Gsk (GLAXF) EBIT Margin (2009 - 2026)
Gsk (GLAXF) recorded quarterly EBIT Margin of 30.06% in Q1 2026, up 135.48% quarter-over-quarter from 12.76% in Q4 2025, and up 57.0% on a YoY basis from 19.14% in Q1 2025.
Gsk (GLAXF) EBIT Margin (2009 - 2026) Analysis & Trends
Gsk's EBIT Margin history runs 18 years deep, the most recent figure standing at 30.06% for Q1 2026.
- In Q1 2026, EBIT Margin rose 57.0% year-over-year to 30.06%; the TTM figure through Mar 2026 stood at 24.47% (up 597.0% YoY), while the FY2025 annual figure was 24.28%, up 1147.0% from the prior year.
- EBIT Margin was 30.06% for Q1 2026 at Gsk, up from 12.76% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 31.89% in Q1 2022 to a low of 2.36% in Q3 2024.
- Historically, EBIT Margin has averaged 23.07% across 5 years, with a median of 23.92% in 2023.
- The sharpest annual moves came in 2024 and 2025: EBIT Margin slumped 2156 bps in 2024, then surged 2798 bps in 2025.
- A 5-year view of EBIT Margin shows it stood at 23.9% in 2022, then advanced by 25 bps to 29.89% in 2023, then tumbled by 31 bps to 20.57% in 2024, then tumbled by 38 bps to 12.76% in 2025, then jumped by 135 bps to 30.06% in 2026.
- The last three EBIT Margin figures came in at 30.06% (Q1 2026), 12.76% (Q4 2025), and 30.34% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 30.06% |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 47.98% |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 26.44% |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 26.60% |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -47.46% |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 30.94% |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 37.16% |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -286.83% |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -1.58% |
| 10 | Gsk | - | - | 7.76 Bn | 30.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.06% |
| Dec 31, 2025 | 12.76% |
| Sep 30, 2025 | 30.34% |
| Jun 30, 2025 | 25.33% |
| Mar 31, 2025 | 29.48% |
| Dec 31, 2024 | 20.57% |
| Sep 30, 2024 | 2.36% |
| Jun 30, 2024 | 20.88% |
| Mar 31, 2024 | 20.24% |
| Dec 31, 2023 | 29.89% |
| Sep 30, 2023 | 23.92% |
| Jun 30, 2023 | 29.83% |
| Mar 31, 2023 | 29.95% |
| Dec 31, 2022 | 23.90% |
| Sep 30, 2022 | 15.21% |
| Jun 30, 2022 | 15.60% |
| Mar 31, 2022 | 31.89% |
| Dec 31, 2021 | 6.95% |
| Sep 30, 2021 | 20.82% |
| Jun 30, 2021 | 21.84% |